Free Trial
NASDAQ:ANIX

Anixa Biosciences Q2 2024 Earnings Report

Anixa Biosciences logo
$2.72 -0.03 (-1.09%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$2.98 +0.26 (+9.52%)
As of 04/17/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anixa Biosciences EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Anixa Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Anixa Biosciences Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Thursday, September 5, 2024
Conference Call Time
8:00PM ET

Upcoming Earnings

Anixa Biosciences' Q2 2025 earnings is scheduled for Tuesday, June 3, 2025

Earnings Documents

Anixa Biosciences Earnings Headlines

Anixa Biosciences receives notice of allowance for new patent from USPTO
Musk’s AI Masterplan – Our #1 AI Stock to Buy Now
Did Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so. Musk has been quietly creating one of the most ambitious AI ventures in history.
See More Anixa Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anixa Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anixa Biosciences and other key companies, straight to your email.

About Anixa Biosciences

Anixa Biosciences (NASDAQ:ANIX), a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

View Anixa Biosciences Profile

More Earnings Resources from MarketBeat